InfuSystem Holdings, Inc (INFU) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Latest close $14.67 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold INFU. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.01% | 620,000 | TRIMMED (-14.1%) Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +47.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 98 of 8,857 filers |
| Long-only filers among them | 98 |
| Change vs 2026 Q1 | +7 net · 97 entered · 90 exited |
| Shares reported, all filers | 15,022,929 |
| Reported value, all filers | $136.1M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus (SIC 3841) |
| Revenue · FY2025 | $143.4M |
| Net income · FY2025 | $6.6M |
| Total assets · FY2025 | $100.6M |
| Shares outstanding | 19,917,181 |
| Market cap (at latest close) | $292.2M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 813,399 |
| Share of shares outstanding | 4.08% |
| Days to cover | 7.63 |
Shares short at recent settlements — Jul 31, 2026: 781K · Aug 14, 2026: 734K · Aug 31, 2026: 755K · Sep 15, 2026: 812K · Sep 30, 2026: 864K · Oct 15, 2026: 813K.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | Shuda Scott | Director | 5,752 | $56.5K | Aug 22, 2025 | SEC filing |
| May 21, 2025 | Richard Dilorio | Director, Officer | 20,000 | $122.0K | May 21, 2025 | SEC filing |
| Nov 25, 2024 | Richard Dilorio | Director, Officer | 40,000 | $373.2K | Nov 25, 2024 | SEC filing |
| Jun 16, 2023 | Lehman Gregg Owen | Officer | 25,000 | $227.7K | Jun 16, 2023 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jan 22, 2025 | SCHEDULE 13D/A | +83.3% (close Jan 23, 2025 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jan 23, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Jul 28, 2026 | BlackRock, Inc. | SC 13G | 1,286,129 | 6.4% | Jun 30, 2026 | SEC filing |
| Feb 17, 2026 | Minerva Advisors LLC | SC 13G/A | 1,078,731 | 5.3% | Dec 31, 2025 | SEC filing |
| Dec 3, 2025 | Minerva Advisors LLC | SC 13G | 1,025,798 | 5.0% | Oct 31, 2025 | SEC filing |
| Nov 13, 2025 | AWM Investment Company, Inc. | SC 13G/A | 561,656 | 2.8% | Sep 30, 2025 | SEC filing |
| Aug 14, 2025 | AWM Investment Company, Inc. | SC 13G/A | 1,272,296 | 6.1% | Jun 30, 2025 | SEC filing |
| Jul 29, 2025 | The Vanguard Group | SC 13G/A | 957,638 | 4.6% | Jun 30, 2025 | SEC filing |
| Jul 17, 2025 | BlackRock, Inc. | SC 13G/A | 402,448 | 1.9% | Jun 30, 2025 | SEC filing |
| May 9, 2025 | AWM Investment Company, Inc. | SC 13G/A | 1,626,280 | 7.7% | Mar 31, 2025 | SEC filing |
| Jan 22, 2025 | Sansone Advisors, LLC | SC 13D/A | 939,294 | 4.4% | Jan 21, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 28 Lobbying Disclosure Act filings named this company as client, 2015–2022; most common issues: Medicare/Medicaid (26), Health Issues (5).
Federal contracts: $225.2K in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $0 |
| FY2022 | $0 |
| FY2023 | $0 |
| FY2024 | $65.7K |
| FY2025 | $113.9K |
| FY2026 | $45.6K |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C26022P0559 | Department of Veterans Affairs | $100.9K | May 1, 2022 |
| 36C24123P0403 | Department of Veterans Affairs | $100.7K | Mar 6, 2023 |
| 75N90018P00870 | Department of Health and Human Services | $71.9K | Sep 25, 2018 |
| HHSN269201800136P | Department of Health and Human Services | $70.0K | Dec 14, 2017 |
| 36C24725P0047 | Department of Veterans Affairs | $69.4K | Nov 1, 2024 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Piotroski — Financial health improved over the past year
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)
Key figures
· Growth — Latest revenue: $143.4M · 5-yr revenue CAGR: 8.1% · Straight growth years: 7
· Graham — Current ratio: 1.80 · Straight profitable years: 7 · Debt ratio: 0.75 · Latest net income: $6.6M
· Piotroski — F-score: 8 · Return on assets: 6.6% · Operating cash flow: $24.4M
· Cash Flow (FCF) — Latest FCF: $23.8M · FCF yield: 7.8% · Positive FCF years: 3
· Gross Profitability (Novy-Marx) — Gross profit / assets: 79.8% · Gross margin: 56.0%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 8.43 · Operating cash flow: $24.4M · Net income: $6.6M
· Shareholder Yield — Shareholder yield: 3.2% · of which dividends: 0.0% · of which buybacks: 3.2%
· Auditor Change (8-K 4.01) — Latest event: Mar 19, 2026 · Events in 2 yrs: 1
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2025 Q2, ranked #29 of 50.
Also held by the tracked funds that hold INFU — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 9, 2026 | 7.01 Regulation FD Disclosure | SEC filing |
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition | SEC filing |
| Nov 3, 2026 | 7.01 Regulation FD Disclosure | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on INFU
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.